Andres Garcia Zuniga, MD
Internal Medicine · Laredo, TXNPI 1962726653
Payments from drug & device makers
Across 153 payments — averaging $1301.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$112K
- Merck$70K
- AstraZeneca$15K
- Novo Nordisk$384
- Amarin Pharma, Inc.$245
- Sanofi-aventis U.S. LLC$211
- plus $1K from 18 others
What the payments were for
- Food & beverage$2,561100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 15 | $112,167 |
| Merck | 29 | $70,493 |
| AstraZeneca | 27 | $14,605 |
| Novo Nordisk | 13 | $384 |
| Amarin Pharma, Inc. | 15 | $245 |
| Sanofi-aventis U.S. LLC | 12 | $211 |
| Bayer | 2 | $156 |
| Johnson & Johnson | 4 | $147 |
| Boehringer Ingelheim | 6 | $102 |
| Sun Pharmaceutical Industries Inc. | 1 | $98 |
| Lilly USA, LLC | 5 | $92 |
| GSK | 4 | $70 |
| Biohaven Pharmaceuticals, Inc. | 1 | $69 |
| Bristol Myers Squibb | 3 | $67 |
| AbbVie | 3 | $59 |
| Abbott | 2 | $36 |
| Arbor Pharmaceuticals, Inc. | 2 | $33 |
| Amgen | 2 | $33 |
| Radius Health, Inc. | 2 | $25 |
| Novartis | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$199,175 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 710 | $900,836 |
| FarxigaDapagliflozin Propanediol | 314 | $352,520 |
| MounjaroTirzepatide | 257 | $329,683 |
| JanuviaSitagliptin Phosphate | 286 | $323,132 |
| EliquisApixaban | 183 | $162,673 |
| JardianceEmpagliflozin | 113 | $159,034 |
| TrulicityDulaglutide | 93 | $151,567 |
| LinzessLinaclotide | 102 | $104,980 |
| Tresiba Flextouch U-200Insulin Degludec | 89 | $89,441 |
| RybelsusSemaglutide | 49 | $87,803 |
| MyrbetriqMirabegron | 92 | $84,909 |
| TradjentaLinagliptin | 67 | $77,794 |
| EntrestoSacubitril/Valsartan | 78 | $74,050 |
| Tresiba Flextouch U-100Insulin Degludec | 112 | $68,622 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 44 | $64,847 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $384 | $988,639759 claims |
| Lilly USA, LLCMounjaro, Trulicity | $92 | $481,250350 claims |
| MerckJanuvia, Janumet Xr, Janumet, Belsomra | $70,493 | $447,527416 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $14,605 | $391,659377 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $102 | $256,818194 claims |
| PfizerEliquis | $112,167 | $162,673183 claims |
| AbbVieLinzess | $59 | $104,980102 claims |
| NovartisEntresto | $21 | $74,05078 claims |
| AmgenProlia | $33 | $39,87923 claims |
| Johnson & JohnsonXarelto | $147 | $35,59643 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $70 | $32,75435 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $211 | $15,89716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Laredo
- Milton HaberLaredo$10.7M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.